Prognostic significance of the sequential detection of circulating melanoma cells by RT–PCR in high-risk melanoma patients receiving adjuvant interferon by Gogas, H et al.
Prognostic signiﬁcance of the sequential detection of circulating
melanoma cells by RT–PCR in high-risk melanoma patients
receiving adjuvant interferon
H Gogas*
,1, G Kefala
1, D Bafaloukos
2, K Frangia
2, A Polyzos
1, D Pectasides
2, D Tsoutsos
2, P Panagiotou
2,
J Ioannovich
2 and D Loukopoulos
1
1Research Laboratory of 1st Department of Medicine, University of Athens; Aghiou Thoma 17, Goudi, Athens 11 527, Greece;
2Hellenic Cooperative Oncology
Group (HeCOG), Data ofﬁce, Laskaridou 1, Athens 11 524, Greece
The purpose of this study was to address the prognostic signiﬁcance of circulating melanoma cells by reverse transcriptase-
polymerase chain reaction in the peripheral blood of stage IIB and III melanoma patients on high-dose adjuvant interferon at
multiple sequential time points from initiation of treatment. Tyrosinase mRNA in peripheral blood from these patients was
assayed by reverse transcriptase polymerase chain reaction prior to initiation of adjuvant interferon, at completion of 1 month
of intravenous interferon and at 3 monthly intervals until progression. Four hundred and eighteen blood samples from 60
melanoma patients were analysed. The median follow-up time calculated from the time of inclusion in the study was 23
months (range 2–38 months). Tyrosinase mRNA in blood was detected in 42 (70%) of 60 patients: 16 (76%) of 21 stage IIB
patients and 26 (66% ) of 39 stage III patients. The presence of tyrosinase mRNA in blood was correlated with a shorter
disease-free survival (P: 0.03) and in multivariante analysis was an indepent prognostic factor for relapse. Patients who
seroconverted to a negative reverse-transcriptase-polymerase chain reaction after induction treatment had a signiﬁcantly lower
probability of recurrence. The presence of circulating melanoma cells is a marker of a high relapse risk and shorter disease-free
survival whether detected postoperatively or during follow-up. Tyrosinase mRNA ampliﬁcation by reverse-transcriptase-
polymerase chain reaction may be a useful tool for monitoring the efﬁcacy of adjuvant treatment in stage IIB and III melanoma
patients.
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For detecting tumour cells in melanoma patients reverse transcrip-
tion-polymerase chain reaction (RT–PCR) has been used to
identify tyrosinase, a key enzyme in melanin biosynthesis, in the
circulation of patients with disseminated disease (Smith et al,
1991). The tyrosinase gene is actively expressed only in melanocytes
and melanoma cells (Kwon et al, 1987) and as melanocytes cannot
be detected in the circulation, the detection of tyrosinase RNA
indicates the presence of melanoma cells.
The relationship between circulating tumour cells and the devel-
opment of secondary disease is not fully understood. The presence
of such cells in peripheral blood samples from early stages melano-
ma could indicate a dissemination of the tumour cells, and thus a
high risk of metastasis. If conﬁrmed circulating melanoma cells
could represent a new prognostic marker with which to predict
clinical behaviour, assess tumour progression, and improve patient
management.
However, different research groups reported conﬂicting results
on the sensitivity and clinical value of tyrosinase RT–PCR (Foss
et al, 1995; Stevens et al, 1996; Jung et al, 1997; Glaser et al,
1997). In patients with localised disease (stages I and II) the
percentage of blood samples that test positive for tyrosinase varies
greatly ranging from 0 (Kunter et al, 1996) to 45% (Reinhold et
al, 1997). Blood samples from untreated patients with advanced
disease show remarkable differences in tyrosinase-positive rates,
which range from 0 to 44% (Battayani et al, 1995) for stage III
patients and from 13% (Pittman et al, 1996) to 100% for stage
IV patients (Brossart et al, 1993). Some groups have found that
RT–PCR for tyrosinase maybe a prognostic marker in both early
and late stages of disease. In one study PCR detection of circulat-
ing melanocytes was considered as a marker for rapid
postoperative relapse after node dissection in patients with mela-
noma and regional node metastases, for short-term relapse in
high-risk disease-free patients and for rapid and severe progres-
sion in patients with distant metastases (Battayani et al, 1995).
Although most of the studies have been focused on the detection
of circulating melanoma cells at the time of initial diagnosis they
can also be detected in blood months or years after primary
tumour diagnosis (Curry et al, 1998).
However the biological and clinical implications that may be
associated with the presence of circulating malignant cells during
the follow-up of melanoma patients are not clear. To address the
prognostic implications of the presence of late circulating melano-
ma cells, we decided to investigate the presence of tyrosinase
mRNA by RT–PCR in the peripheral blood of stage IIB and III
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y
Received 3 December 2001; revised 8 April 2002; accepted 29 April 2002
*Correspondence: H Gogas, Lecturer in Medical Oncology, 1st Depart-
ment of Medicine, University of Athens, P.O. BOX 14120, Athens
11510, Greece; E-mail: hgogas@hol.gr
British Journal of Cancer (2002) 87, 181–186
ã 2002 Cancer Research UK All rights reserved 0007–0920/02 $25.00
www.bjcancer.commelanoma patients on high-dose adjuvant interferon a-2b at multi-
ple sequential time points from initiation of treatment.
MATERIALS AND METHODS
Patients
Patients with a histologically documented diagnosis of cutaneous
melanoma, stage IIB or III according to the American Joint
Committee on Cancer (AJCC) guidelines were included in the
study. Stage was deﬁned on a pathological basis. Patients under-
went sentinel node dissection. Any patient with a positive SLN
was required to undergo a complete lymphadenectomy. All patients
were initiated on high-dose inteferon according to Hellenic Coop-
erative Oncology Group protocol (Gogas et al, 2000) 2 months
after initial surgery, or 1.5 months after therapeutic lymph node
dissection for regional lymph node recurrence. Oral informed
consent was obtained from each patient. Blood for tyrosinase
RT–PCR was drawn at the same time that blood extraction was
performed for previous established follow-up: the ﬁrst 20 ml of
blood collected were used for standard biochemistry and cell blood
counts, and the following 15 ml were used for RT–PCR studies.
Blood samples were obtained prior to induction treatment, at
completion of 1 month intravenous interferon, and at 3 monthly
intervals until progression. The clinical outcome of patients was
prospectively followed. Clinical staging consisted of medical
history, physical exam, cell blood count, blood biochemistry at 3
monthly intervals, chest X-ray and liver ultrasound at 6 monthly
intervals. Other complimentary exams were performed if they were
clinically indicated. Patients with a positive RT–PCR were not
subjected to a more intensive follow-up than were those with a
negative RT–PCR and no clinical decisions were made based on
the results of the RT–PCR assay. Negative controls were healthy
subjects and patients with other malignancies.
Samples - RNA extraction
Twelve to 15 ml of blood were collected in EDTA anticoagulant
from each patient. The mononuclear cell fraction of peripheral
blood was isolated by ﬁcoll gradient centrifugation (Boyum,
1968). Total RNA was isolated from the mononuclear cell fraction
by guanidium thiocyanate extraction (Chomczynski and Sacchi,
1987). The extracted RNA was dissolved in ddH20. Integrity was
evaluated by assesing the 18 S and 28 S ribosomal RNA bands in
2% ethidium-bromide-stained agarose gel. The amount of RNA
was calculated by spectrophotometric analysis.
Complementary DNA synthesis
For the complementary DNA (cDNA) synthesis 1 mg of RNA was
incubated for 5 min at 658C with 3 mg Random Primer oligonu-
cleotides (Gibco-BRL), in a total volume of 13 ml. One mM of
each deoxynucleotide triphospate (dNTP) (New England Biolabs),
16 First Strand Buffer and 200 U Moloney Murine Leukemia
Virus Reverse Transcriptase (M-MLV RT) (Gibco BRL), were
added to a ﬁnal volume of 20 ml. cDNA synthesis was performed
for 1 h at 378C, followed by enzyme denaturation at 958C for
2 min.
The Retinoic Acid Receptor a (RARa) gene was used as an inter-
nal control for assessing the quality of the cDNA. Effective
ampliﬁcation using the primers RaR6 and RaR8 conﬁrmed the
quality of the samples.
PCR method
Ten ml of the previously obtained cDNA sample were ampliﬁed in
the ﬁrst PCR round using 100 pmol of each primer HTYR1 (sense:
TTG, GCA, GAT, TGT, CTG, TAG, CC) and HTYR2 (antisense:
AGG, CAT, TGT, GCA, TGC, TGC, TT) (Smith et al, 1991).
The reaction mixture also contained 0.2 mM of each dNTP,
16PCR buffer, 2 mM MgCl2 and 2 U Taq DNA Polymerase
(Gibco BRL) in a ﬁnal volume of 50 ml.
The PCR began with one cycle of 5 min at 948C for template
denaturation, followed by 30 cycles of 1 min denaturation at
948C, 1 min at 558C for primer annealing and 1 min for polymer-
ase extension at 728C. The reaction was terminated with a 10 min
extension at 728C. Five ml of a 1:100 dilution of the ﬁrst-round
PKR product were reampliﬁed using the nested primers HTYR3
(sense: GTC, TTT, ATG, CAA, TGG, AAC, GC) and HTYR4 (anti-
sense GCT, ATC, CCA, GTA, AGT, GGA, CT) (1) in a 25 ml ﬁnal
volume, for a further round of 30 cycles under the same conditions
as the ﬁrst PCR round.
The outer primers amplify a PCR, product of 284 base pairs,
while the nested primers amplify a fragment of 207 base pairs.
The PCR products were visualised in ethidium bromide-stained
3% agarose gel.
To determine the sensitivity of the assay serial dilutions of 10
6 to
1 SK-Mel 28 cells in 10
7 normal mononuclated peripheral blood
cells, were prepared. RT–PCR was performed using 1 mg of total
RNA from each dilution. The sensitivity of the method was high
enough to detect 10 SK-Mel 28 cells in 10
7 normal cells. Southern
blot was performed to conﬁrm that our RT–PCR ampliﬁed
products were indeed from tyrosinase.
Statistical analysis
Relapse free survival was calculated from the initiation of treatment
to the date relapse of the disease (RFS) was ﬁrstly documented and
overall survival (OS) from initiation of treatment to the date of
death or last contact. All patients without the corresponding event
by 30/9/00 were considered censored. Sensitivity was calculated as
the proportion of relapsed patients with positive RT–PCR. Speci-
ﬁcity as the proportion of non-relapsed patients with negative RT–
PCR. Positive predicted value as the proportion of positive RT–
PCR patients with relapse. Negative predicted value as the propor-
tion of negative RT–PCR patients without being relapsed.
The w
2 test were used to test the association between RT–PCR
status and stage, Breslow, Clark, ulceration, regression, lymph node
status, primary tumour location, sex, age. The Kaplan–Meier
method was used to calculate RFS and OS curves, while the log-
rank test was used to compare time to event distributions. Multi-
variate analysis were performed with Cox proportional hazard
models in order to indicate independent prognostic factors for
survival and relapse-free survival. A backward selection procedure
identiﬁed the subclass of signiﬁcant variables among the following:
stage (IIB vs III), Breslow (0–2 vs 2.1–444), Clark (II–III vs IV
vs V), ulceration (No vs Yes), regression (No vs Yes), lymph node
status (No vs Yes) primary tumour location, sex (male vs female),
age (552 vs 52). The signiﬁcant factors were kept in the model if
the maximum likelihood ration criterion had a P-value below 0.10.
All reported P-values are two-sided.
Calculations were made using each patient. A negative patient is
a patient whom no positive result has ever been obtained and a
positive patient, is a patient in whom at least one positive test
has been obtained. As all patients with positive sentinel lymphnode
had undergone lymphadenectomy, no nodal relapses were seen in
our study population and relapses are distant metastasis.
RESULTS
Patients
Four hundred and eighteen blood samples from 60 melanoma
patients were tested for tyrosinase mRNA in blood by RT–PCR.
The median number of RT–PCR tests per patient was seven (range
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cancer and four patients with colon cancer) was also examined.
Patient’s characteristics are described in Table 1. The patients were
followed for a median time (calculated from the inclusion in the
study) of 23 months (range 2, 738+months, 95% CI 17.4–28.6).
RT–PCR status and relapses
RNA samples that showed the 28 S and 18 S ribosomal band were
considered eligible for the study (Figure 1A). Samples showing a
band of 207 bp after a second round of ampliﬁcation with nested
primers are considered positive (Figure 1B). Using the same RT–
PCR technique no false-positive results among 16 samples from
non melanoma control patients (eight healthy subjects and eight
patients with other cancers). Hence, no illegitimate transcription
in the haematopoietic cells was observed among the non melanoma
controls with the experimental conditions used.
Here 105 (25%) of 418 blood samples were positive for tyrosi-
nase. Circulating melanoma cells were detected in 42 of 60
patients. There was no correlation between RT–PCR status and
age, sex, Breslow, Clark, ulceration, regression, lymph node invol-
vement and stage. Prior to initiation of induction treatment with
intravenous interferon 30 patients had negative RT–PCR, and 30
had positive. After completion of 1 month of induction treatment
16 patients were tested with a negative RT–PCR and 14 continued
to test positive. In the group of patients who initially had a nega-
tive RT–PCR result, 21 had a second negative result and nine
seroconverted, to a positive result, after 4 weeks of intravenous
high-dose interferon. Eighteen patients had sequential negative
RT–PCRs and 42 patients had one or more positive blood samples
for tyrosinase. With a median follow-up of 23 months 29 patients
have recurred and 13 have died from melanoma dissemination.
One patient has died, remaining disease-free. Eighteen patients
had a positive RT–PCR at initiation of adjuvant treatment, eight
tested positive during follow-up and ﬁnally three had sequential
negative RT–PCRs even at relapse. The sites of relapse for these
RT–RCR negative patients were subcutaneous tissue (1), lymph
nodes (2). The median interval between the detection of a positive
RT–PCR result and the diagnosis of clinical relapse was 21 months
(range 1–36 months, 95% CI 11.7–20.3). In the group of patients
with no evidence of disease, 15 had multiple negative RT–PCRs,
nine had a positive sample prior to induction therapy and negative
results during treatment and further follow-up, two had initially
two positive RT–PCRs (one prior to induction therapy and at
completion of intravenous interferon) and negative samples during
maintenance treatment and further follow-up, and ﬁnally ﬁve
patients had more than one positive sample during follow-up
(Table 2).
The RT–PCR positivity by tyrosinase mRNA in blood during
follow-up of patients with melanoma signiﬁcantly correlated with
shorter disease-free survival (P:0.029). The median disease-free
survival was 21 months (95% CI 12.7–29.3) for the RT–PCR
positive group. The median disease-free survival was not reached
for the group of patients testing negative for tyrosinase in blood
(Figure 2). Median overall-survival was not reached for either
group of patients (Figure 3).
In univariante analysis for relapse free survival only RT–PCR
status was correlated with relapse (P: 0.03) (Table 3). In univar-
iante analysis for survival no variable was found to be correlated
with RT–PCR status (Table 4). In multivariante analysis (Cox
regression analysis) RT–PCR status was the only independent
prognostic factor for relapse (b=1.3, 95% CI=0.1–2.5, P-
value=0.03). No independent prognostic factor was found for over-
all survival. Multivariate analysis was performed without the factors
ulceration and regression because of large numbers of unknown
values and the results were exactly the same as these mentioned
above.
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Table 1 Patients characteristics
No. of patients
Total no. 60
No. of males/no. of females 34/26
Median age (yrs) 52 (range 27–78)
Stage (AJCC)
IIB 21
III 39
Histology
Superﬁcial spreading 21
Nodular 26
Acral letiginous 4
Other 7
MLM 2
Primary site
Lower extremities 22
Upper extremities 8
Trunk 18
Head and neck 8
Mucosal 2
Unknown 2
Clark
II–III 9
IV 37
V6
Unknown 8
Breslow
0–2 7
2.1–4 15
443 5
Unknown 3
Regression
No 31
Yes 12
Unknown 17
Ulceration
No 15
Yes 31
Unknown 14
28 S
18 S
A
284 bp
207 bp
B
Figure 1 (A) 28 S and 18 S rRNA bands. Total RNA extraction as vi-
sualised in ethidium bromide stained 2% agarose gel. (B) Ethidium bro-
mide-stained gel visualisation of RT–PCR products showing a 207 bp
band in the positive samples. Lane 1. Molecular Weight Marker (FX174
RF DNA HaeIII Digest). Lanes 2–4. Positive samples (three melanoma pa-
tients). Lanes 5–7. Negative samples (three melanoma patients). Lane 8.
Positive control (SK-mel 28 cell line). Lane 9. Negative control (healthy do-
nor). Lane 10. Negative control (sample without cDNA).
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recurrent disease) was 89.66% (95% CI=72–98%) and the speciﬁ-
city (probability that a patient who tests negative remained disease-
free) was 48.39% (95% CI=30–67%). The positive predictive value
was 61.90% (95% CI=46–76%) and the negative predictive value
was 83.33% (95% CI=59–96%).
There was a statistically signiﬁcant difference in the proportion
of patients remaining disease-free and patients with negative (15
out of 18=83%) and those with positive RT–PCR (16 out of
42=38%) (P=0.002). There was evidence that the proportion (9
out of 11=82%) of seroconverted patients (patients who had a
positive RT–PCR prior to induction therapy and negative RT–
PCRs during treatment and further follow-up) remaining disease-
free was statistically signiﬁcantly higher than that (7 out of
31=23%) of patients being positive (P=0.001). Furthermore, there
was not any evidence that the proportion of seroconverted patients
remaining disease-free was statistically signiﬁcantly higher than that
(15 out of 18=83%) of patients being negative (P=0.92).
DISCUSSION
Conﬂicting results have been obtained by various research groups
using tyrosinase reverse transcription–polymerase chain reaction
(RT–PCR) for detecting micrometastases in the blood of melano-
ma patients, with positive results ranging from 0 to 100% in
disseminated melanoma. Methological differences in the processing
of blood samples may in part account for these discrepancies. The
prognostic signiﬁcance of the detection of circulating melanoma
cells by RT–PCR has been evaluated in several studies. In high-risk
but apparently disease-free patients, the risk of relapse within the
next 6 months was 3.8 times higher after a positive test result, than
after negative PCR test (P: 0.002), and in patients with distant
metastases after a positive PCR, rapid progression was four times
more likely than slow progression or stable disease (Battayani et
al, 1995). In another study patients with a positive PCR showed
a 2.4-fold increased risk for relapse compared with PCR-negative
patients (Schittek et al, 1999). The Melanoma Cooperative Group
performed RT–PCR using tyrosinase, p 97, MUC 18, and Mela-
nA/MART1 as gene markers in 235 patients with either localised
or metastatic melanoma. Univariante analysis showed a signiﬁcant
correlation between risk of recurrence (evaluated in stage I, II and
III patients and increasing number of PCR-positive markers (P:
0.0002). Logistic regression multivariante analysis indicated that
each single marker (except tyrosinase) and more especially, the
presence of PCR-positive markers remained a statistically indepen-
dent prognostic factor for tumour progression (Pialmieri et al,
1999). Finally in one study conducted in long-term clinically
disease-free melanoma patients, regardless of their initial clinical
stage, the presence of late circulating melanoma cells was signiﬁ-
cantly associated with a subsequent high risk of relapse and
death (Mellado et al, 1999).
Here we speciﬁcally studied high-risk melanoma patients to
assess the clinical signiﬁcance of the sequential detection of circu-
lating melanoma cells. The ﬁrst ﬁnding from our data was that one
or more positive tests for tyrosinase mRNA in blood during long-
term follow-up of patients with melanoma was signiﬁcantly corre-
lated with a higher risk of relapse, shown both in univariante and
multivariante analysis but not a higher risk of death from melano-
ma dissemination as found in other studies (Mellado et al, 1999).
Maybe longer follow-up is warranted as median overall survival has
not been reached by either tyrosinase positive or negative group. In
another study (Curry et al, 1998) where blood samples from 276
melanoma patients were tested for tyrosinase and MART-1 at
multiple sequential time points for at least 2 years after surgery,
a low incidence of RT–PCR positivity was observed even up to
2 years after surgery. This occurred both in patients who had been
continuously positive and in patients who had developed positive
results after several negative results. Given the short follow-up of
the patients, the authors could not assess, the prognostic signiﬁ-
cance of their late RT–PCR positive results and consequently
could not exclude that these were false positive results. However
the poor prognosis observed in our group of patients with a posi-
tive RT–PCR presented here suggest that these positivities are due
to the presence of melanoma cells in the circulation in disease-free
patients rather than those false-positive tests. This is also supported
by the worst prognosis reported in other studies evaluating the role
of the late circulating melanoma cells in long-term disease-free
patients (Mellado et al, 1999).
Only three out of 18 patients with sequential negative RT–PCRs
recurred (16.6%), a difference which was statistically signiﬁcant.
Two out of 11 patients who tested positive prior to induction ther-
apy and subsequently had negative RT–PCRs during treatment
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y
TTP
1.0
0.5
0.0
P
r
o
b
a
b
i
l
i
t
y
0                       10                      20                      30                      40
Months
Figure 2 RT–PCR results and relapse-free survival in stage IIB and III
melanoma patient calculated by the Kaplan–Meier method.
OS
1.0
0.5
0.0
P
r
o
b
a
b
i
l
i
t
y
0                       10                      20                      30                      40
Months
Figure 3 RT–PCR results and overall survival in stage IIB and III melano-
ma patients calculated by the Kaplan–Meier method.
Table 2 RT–PCR status and relapses
Sequential negative 3 out of 18
Initial positive and sequential negative 2 out of 11
Positive RT–PCR anytime 24 out of 31
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ent.
On the basis of this observation, it is reasonable to speculate
that the late circulating melanoma cells detected in our patients
can be shed from secondary organs. If this were true then the
presence of circulating malignant cells in the setting of high-risk
melanoma patients would be a marker of the existence of micro-
metastatic disease.
Patients who seroconverted to a negative RT–PCR result after
induction treatment with intravenous interferon, had a signiﬁcantly
lower probability of recurrence. Even though, this is not a rando-
mised study, and there were no untreated patients, and one could
speculate that the conversion was a consequence of greater time
after surgery, the surgery in this case either dislodging tumour cells
or removing the source of tumour cells, the lower probability of
recurrence strongly argues that the reversion was a consequence
of interferon therapy. These results cannot be extrapolated to the
general stage II and III population as IFN may have interfered with
the results.
A negative RT–PCR result did not exclude tumour progression,
as patients with sequential negative RT–PCRs developed metas-
tases. Reasons proposed by other investigators might be that (i)
melanoma cells are shed only intermittently from the tumours into
the circulation; (ii) the lymph nodes work as a ﬁlter for tumour
cells in the circulation, and (iii) the sensitivity of the RT–PCR
is still suboptimal and not all melanoma cell transcripts can be
detected (Schittek et al, 1999). Another probable explanation for
the three patients who developed recurrent disease despite negative
RT–PCR tests is that the recurrent melanoma was tyrosinase nega-
tive. Unfortunately tumour specimens from recurrences were not
tested for tyrosinase expression.
In conclusion our data suggests that circulating melanoma cells
are markers of a high relapse risk and shorter disease-free survival
whether detected postoperatively or during follow-up. Tyrosinase
mRNA ampliﬁcation by RT–PCR may be a useful tool for moni-
toring the efﬁcacy of adjuvant treatment in stage IIB and III
melanoma patients.
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